Dataset Information

The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis.

ABSTRACT: Increased glycolysis is one of the hallmarks of cancer. The abnormal expression of glucose transporter 1 (GLUT1) was reported to be associated with resistance to current therapy and poor prognosis. Numerous studies have investigated the correlation between GLUT1 expression and prognosis in cancers, but the conclusions are still controversial. Here, we conducted a meta-analysis to explore the association between GLUT1 and survival in human cancers. PubMed, Springer, Medline, and Cochrane Library were searched carefully to identify eligible studies evaluating prognostic value of GLUT1 in cancers. Twenty-seven studies with 4079 patients were included in the present study. Our pooled results identified that increased expression of GLUT1 was associated with unfavorable overall survival (HR = 1.780, 95% CI = 1.574-.013, p < 0.001)) and poorer disease-free survival (HR = 1.95, 95% CI = 1.229-3.095, p = 0.003). Furthermore, overexpression of GLUT1 linked with poor differentiated tumors (RR = 1.380, 95% CI = 1.086-1.755, p = 0.009; I2 = 72.0%, p < 0.001), positive lymph node metastasis (RR = 1.395, 95% CI = 1.082-1.799, p = 0.010; I2 = 70.8%, p = 0.002) and larger tumor size (RR = 1.405, 95% CI = 1.231-1.603, p < 0.001; I2 = 37.3%, p = 0.093). This systematic review and meta-analysis indicated that the GLUT1 may serve as an ideal prognostic biomarker in various cancers.

SUBMITTER: Yu M

PROVIDER: S-EPMC5522151 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis.

Yu Min M Yongzhi Han H Chen Shengying S Luo Xiaodan X Lin Ye Y Zhou Yu Y Jin Haosheng H Hou Baohua B Deng Yanying Y Tu Lei L Jian Zhixiang Z

Oncotarget 20170601 26

Increased glycolysis is one of the hallmarks of cancer. The abnormal expression of glucose transporter 1 (GLUT1) was reported to be associated with resistance to current therapy and poor prognosis. Numerous studies have investigated the correlation between GLUT1 expression and prognosis in cancers, but the conclusions are still controversial. Here, we conducted a meta-analysis to explore the association between GLUT1 and survival in human cancers. PubMed, Springer, Medline, and Cochrane Library ...[more]

PMID: 28498810

Similar Datasets

Project description:BACKGROUND:Dysregulation of the long non-coding RNA small nucleolar RNA host gene 16 (lncRNA SNHG6) has been found in multiple cancers. However, a definite conclusion on the clinical value of lncRNA SNHG6 expression in human cancers has not been determined. The purpose of the present meta-analysis was to comprehensively elucidate the association between SNHG6 expression and clinical outcomes in cancers. METHODS:A systematic search was performed through the PubMed, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wangfang databases for relevant studies. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were collected to estimate the prognostic value, and the odds ratios (ORs) with 95% CIs were used to evaluate the relationship between lncRNA SNHG6 expression and clinicopathological features, including tumor invasion depth, lymph node metastasis (LNM), distance metastasis (DM), and TNM stage. RESULTS:In total, 914 patients from 13 studies were included in this meta-analysis. The pooled results suggested that evaluated SNHG6 expression could predict an unfavorable overall survival (OS) (HR?=?2.04, 95% CI:1.56-2.52) with no heterogeneity (I2?=?0.0%, p?=?0.996). Subgroup analysis indicated a significant association between high SNHG6 expression and shorter OS in those studies with digestive system cancers (HR?=?2.05, 95% CI: 1.47-2.62), or with sample size <?70 (HR?=?2.70, 95% CI: 1.29-4.11), or with multivariate analysis (HR?=?2.04, 95% CI: 1.44-2.64). Moreover, elevated SNHG6 expression was positively associated with tumor invasion depth (OR?=?1.76, 95% CI: 1.18-2.63), LNM (OR?=?1.60, 95% CI: 1.18-2.17), DM (OR?=?1.90, 95% CI: 1.37-2.64) and advanced TNM stage (OR?=?1.88, 95% CI: 1.36-2.60) in patients with cancers. CONCLUSIONS:High lncRNA SNHG6 expression was correlated with tumor invasion depth, LNM, DM, and advanced TNM stage, suggesting that SNHG6 may serve as a promising prognostic biomarker of human cancers.

Dataset Information

The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis.

Publications

The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets